A Safety Study of Mirikizumab (LY3074828)

NCT01947933 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

BIOLOGICAL: Mirikizumab- IV
BIOLOGICAL: Mirikizumab - SC
BIOLOGICAL: Placebo - IV

Sponsor

Eli Lilly and Company